University of California: Combination of Immunotherapy and Targeted Therapy Improves Survival for Patients With Advanced Colorectal Cancer
October 24, 2025
October 24, 2025
LOS ANGELES, California, Oct. 24 (TNSjou) -- The University of California issued the following news release:
* * *
Combination of immunotherapy and targeted therapy improves survival for patients with advanced colorectal cancer
A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer, the second most common cause of c . . .
* * *
Combination of immunotherapy and targeted therapy improves survival for patients with advanced colorectal cancer
A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer, the second most common cause of c . . .